Sepp-Lorenzino Laura

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
8
Insider Sells Sum
$19.26M

Insider Activity of Sepp-Lorenzino Laura

According to the SEC Form 4 filings, Sepp-Lorenzino Laura, being in a position of

  1. EVP, Chief Scientific Officer at Intellia Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 8966 shares for $109,206,
    over all time since 2021-08-04, has bought 0 shares, and sold 145759 shares for $19.26M.

The largest sale of all time was on 2021-08-30 and amounted to 97000 shares of Intellia Therapeutics, Inc. for $15.02M.

Biography of Sepp-Lorenzino Laura

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$109,2061100

Comparison of Insiders on Amount of Buys and Sells

2025-01-03SaleIntellia Therapeutics, Inc.
NTLA
EVP, Chief Scientific Officer
8,966
0.0088%
$12.18$109,206-16.82%
2024-01-08SaleIntellia Therapeutics, Inc.
NTLA
EVP, Chief Scientific Officer
2,275
0.0025%
$28.87$65,682-23.71%
2024-01-03SaleIntellia Therapeutics, Inc.
NTLA
EVP, Chief Scientific Officer
5,532
0.0062%
$29.46$162,973-22.09%
2023-01-05SaleIntellia Therapeutics, Inc.
NTLA
EVP, Chief Scientific Officer
2,330
0.0026%
$38.48$89,659-2.68%
2023-01-04SaleIntellia Therapeutics, Inc.
NTLA
EVP, Chief Scientific Officer
2,508
0.0027%
$37.21$93,323-3.42%
2022-01-01SaleIntellia Therapeutics, Inc.
NTLA
EVP, Chief Scientific Officer
1,148
0.0015%
$112.25$128,863-50.72%
2021-08-30SaleIntellia Therapeutics, Inc.
NTLA
EVP, Chief Scientific Officer
97,000
0.1324%
$154.83$15.02M-48.07%
2021-08-04SaleIntellia Therapeutics, Inc.
NTLA
EVP, Chief Scientific Officer
26,000
0.0332%
$138.24$3.59M-37.8%
Total: 8
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.